EVAX ▼ -2.2% - Evaxion A/S $EVAX - Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 23-OCT-2026 02:00 AM ET